Is The Pfizer Takeover Offer for AstraZeneca plc ‘Un-American’?

Pfizer Inc. (NYSE:PFE) has AstraZeneca plc (LON:AZN) firmly in its sights as a home for the $69bn of earnings it has stashed in offshore tax havens

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The spotlight is on Pfizer (NYSE: PFE.US) right now as its record-breaking offer of $106.43bn for UK-based pharmaceutical giant AstraZeneca (LSE: AZN) (NYSE: AZN.US) is causing a ruckus in government corridors on both sides of the Atlantic.

In the US, Senators are attempting to draft legislation that will put a halt to large corporations deserting the US to save tax. Commentators are branding Pfizer ‘Un-American’ as it makes no secret that the buyout is primarily a tax-planning scheme, and if the deal is successful it will relocate its tax residence to the UK. It has AstraZeneca firmly in its sights as a home for the $69 billion of earnings it has stashed in offshore tax havens and which it promised never to repatriate to the US to avoid a 39% US corporation tax bill.

On this side of the Atlantic, politicians are fearful that if Pfizer is successful it will repeat its behavior of 2011 when it laid off thousands of employees and closed down R&D factory in Sandwich, Kent to save costs.

According to Sweden’s finance minister, Anders Borg, Pfizer also failed to keep promises made to them on research jobs when it bought Swedish drug-maker Pharmacia in 2002.

MPs are demanding the government applies a ‘public interest stress test’ for this merger and, having examined the small print, the suits in Whitehall have discovered that the legislation does not include life science companies. The government can only intervene on mergers or takeovers where there is a national security issue, media plurality, competition concerns or national financial stability. Vince Cable told MPs “One of our options as the government would be to consider using our public interest test powers. But we are operating within serious European legal constraints.”

UK ministers have so far got assurances from Pfizer that include a commitment from the US firm to complete AstraZeneca’s planned scientific campus in Cambridge, to base 20% of the new company’s research and development workforce in the UK and to manufacture more products here, but it is not clear how these promises will be sanctioned.

AZNThe British Tax Bounty

The UK government has been actively pursuing a strategy to win multinational tax dollars. By 2015 the corporation tax rate will be reduced to 22%, with Chancellor George Osborne boasting that this would “give Britain the lowest tax rate of the Group of Seven leading industrial countries”.  It has also introduced a new regime that from 2017 will mean income from patents will be taxed at just 10%. With the whopping 130% tax relief already available on research and development expenditure, there is a strong value proposition for pharmaceutical and technology companies to base themselves in the UK.

The government’s tax policy has certainly seen some successes, as not only are US companies relocating to the UK, but WPP moved back to the UK from Ireland after just four years.

Companies are increasingly shopping the world for low tax regimes, and competition among nations will hot up as governments choose to use tax incentives as tools to stimulate their economies. As global institutions take a transient approach to their resident status, we can expect shifting dynamics for years to come.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Lisa Walls-Hester does not own shares in any of the above companies.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »